## Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC)

John N. Brewin,<sup>1,2</sup> Helen Rooks,<sup>1</sup> Kate Gardner,<sup>1,3</sup> Harry Senior,<sup>1</sup> Mrinmayi Morje,<sup>1</sup> Hamel Patel,<sup>1</sup> David Calvet,<sup>4</sup> Pablo Bartolucci,<sup>4</sup> Swee-Lay Thein,<sup>5</sup> Stephan Menzel<sup>1#</sup> and David C. Rees<sup>1,2#</sup>

<sup>1</sup>Kings College London, UK; <sup>2</sup>Kings College Hospital, London, UK; <sup>3</sup>Guys and St Thomas Hospital, London, UK; <sup>4</sup>Henri Mondor Hopital, Paris, France and <sup>5</sup>NIH, Bethesda, USA

\*SM and DCR contributed equally as co-senior authors.

Correspondence: JOHN BREWIN - john.brewin@kcl.ac.uk doi:10.3324/haematol.2020.265827 Supplementary Figure 1: Results of genome wide association testing of SCI outcomes in patients with sickle cell disease. Age, gender, sickle genotype and alpha thalassemia were used as covariates, and a genetic relatedness included to control for population structure. The QQ plot (A) demonstrates no genomic inflation which would be suggestive of population stratification bias. The Manhattan plot (B) demonstrates the p values of the variants analysed. The blue line represents 1x10<sup>-5</sup>, whilst the red line represents 5x10<sup>-8</sup> which was used as the threshold of statistical significance.



## Supplementary table 1 The top five variants identified in the GWAS described in supplementary figure 1.

Gene	rsID	Change	MAF	OR	р	Variant location	Gene Function
CHSY3	rs1557759	G>A	0.222	0.44	1.88E-06	Upstream variant	Glycosyltransferase
PHACTR2	rs6930487	G>A	0.388	1.94	1.96E-06	Intronic	Platelet response to cytosolic Ca <sup>2+</sup>
None	rs201658643	G>GTA	0.318	2.08	2.34E-06	Intergenic	NA
TOX4	rs10142478	A>C	0.067	0.25	2.76E-06	Intronic	Chromatin Binding
PRKACB	rs2250806	A>G	0.415	0.51	2.88E-06	Intronic	Mediates cAMP-dependent signalling